“We also applaud TG Therapeutics for pricing Briumvi significantly lower than other MS therapies, helping to increase access and enable more people with MS to potentially benefit from this new therapy.”

For patient investors, Axsome Therapeutics is well-positioned to deliver solid returns over the next five years and beyond as it develops and launches new medicines and earns key label expansions for its existing ones.

$AXSM 2 Promising New Growth Stocks to Watch in 2023 Axsome Therapeutics (AXSM 4.08%) actually beat the bear market last year.

$AXSM 2 Stocks That Could Double Your Money in 2023 Axsome Therapeutics Axsome Therapeutics is a mid-cap drugmaker coming off a solid performance in 2022, during which its shares more than doubled.

$AXSM Axsome Therapeutics announces that treatment with AUVELITY resulted in rapid, substantial, and durable improvements in cognitive and physical functioning in the EVOLVE open-label trial in major depressive disorder.

$AXSM good Therapeutics, they bought Sunosi for the Cash Pipeline and get FDA approval 'Auvelity 'and still have more AXS series

$AXSM NEW ARTICLE : Analysts Are Bullish on These Healthcare Stocks: Axsome Therapeutics (AXSM), Vaxcyte (PCVX) https://www.stck.pro/news/AXSM/37221581

$AXSM Axsome Therapeutics stock nice move off support, local breakout , see https://stockconsultant.com/?AXSM @StockConsultant

$AXSM Axsome Therapeutics stock back to 43 support area with bullish stats , see https://stockconsultant.com/?AXSM @StockConsultant